Fig. 9
![Fig. 9](http://media.springernature.com/full/springer-static/image/art%3A10.1186%2Fs12951-021-01201-y/MediaObjects/12951_2021_1201_Fig9_HTML.png)
Antitumor capacity in vivo. A Schedule of the targeted PDT. B Photographs of tumors harvested from mice after various treatments (n = 5) and HOS tumor-bearing mice before sacrifice. C Tumor volume was measured during the therapeutic period. (The data are presented as the mean ± SD values; n = 5, *p < 0.05, **p < 0.01.) D Tumor weights were recorded at the end of therapy. (The data are presented as the mean ± SD values; n = 5, *p < 0.05, **p < 0.01). E H&E staining and images of PCNA and Ki67 immunohistochemical staining in tumor specimens after various treatments. The scale bars represent 100 µm